Lupin names Shahin Fesharaki as Global Chief Scientific Officer

7 Oct 2022 , 09:17 AM

Lupin Limited announced the appointment of Shahin Fesharaki as Global Chief Scientific Officer. Fesharaki will be in charge of Lupin’s global R&D operations spanning branded, generic, and specialty products.

Fesharaki has approximately 30 years of expertise in drug development with prominent global pharmaceutical firms, most recently serving as Hikma Pharmaceuticals’ Chief Scientific Officer and Global Head of R&D. Fesharaki formerly held roles of increasing responsibility in Teva, Allergan/Actavis, Watson Pharmaceuticals, and Apotex.

“We are delighted to welcome Shahin to our leadership team,” stated Vinita Gupta, CEO, and Nilesh Gupta, MD, Lupin, in response to the appointment. “Shahin’s remarkable track record of delivering brands and generics in developed and emerging countries will be invaluable as we accelerate our transition into complicated generics and specialties while driving growth in all of our main markets.”

Fesharaki has considerable development expertise in both generic and branded medications, spanning across several technologies and dosage forms.

At around 9.20 AM, Lupin was trading at Rs723.10 up by 0.01% from its previous closing of Rs723.05 on the BSE. The scrip opened at Rs718 and touched intraday high and low of Rs723.70 and Rs718 respectively. 

For feedback and suggestions, write to us at [e-mail]